Medically reviewed by Drugs.com. Last updated on Jan 1, 2020.
Applies to the following strengths: 60 mg/1.5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Prostate Cancer
25 mg/m2 IV over 1 hour every three weeks
-Use in combination with prednisone or prednisolone.
-Give premedication regimen at least 30 minutes prior to each administration.
-Give antiemetics prophylactically or as needed.
-Ensure adequate hydration throughout treatment.
Use: Use in combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing regimen.
Renal Dose Adjustments
CrCl 50 to 80 mL/min: No adjustment necessary
CrCl less than 50 mL/min or end stage renal disease: Use with caution and monitor carefully during treatment.
Liver Dose Adjustments
Adjust dosage for the following adverse events:
-Prolonged (more than 1 week) Grade 3 or higher neutropenia despite appropriate medication including G-CSF: Delay treatment until neutrophil count is greater than 1,500 cells/mm3, then reduce dose to 20 mg/m2.
-Febrile neutropenia or neutropenic infection: Delay treatment until improvement or resolution, and neutrophil count is greater than 1,500 cells/mm3, then reduce dose to 20 mg/m2.
-Grade 3 or higher, or persisting diarrhea despite appropriate medication, fluid, and electrolytes replacement: Delay treatment until improvement or resolution, then reduce dose to 20 mg/m2.
-Grade 2 or higher peripheral neuropathy: Delay treatment until improvement or resolution, then reduce dose to 20 mg/m2.
-Discontinue treatment if patient continues to experience any of these reactions at 20 mg/m2.
US BOXED WARNINGS:
-Neutropenic deaths have been reported.
-In order to monitor the occurrence of neutropenia, frequent blood cell counts should be performed on all patients.
-This drug should not be given to patients with neutrophil counts of 1,500 cells/mm3 or less.
-Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.
-Severe hypersensitivity reactions require immediate discontinuation of the infusion and administration of appropriate therapy.
-Patients should receive premedication.
-This drug must not be given to patients who have a history of severe hypersensitivity reactions to this drug or to other drugs formulated with polysorbate 80.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Do not use PVC infusion containers for preparation or infusion.
-Do not use polyurethane infusion sets for administration.
-Use an in-line 0.22 micrometer filter during administration.
Storage requirements: Do not refrigerate.
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
IV compatibility: Do not mix with other medications.
-Administer under the supervision of a physician experienced in the use of antineoplastics.
-Facilities and equipment for the treatment of serious hypersensitivity reactions, like hypotension and bronchospasm, must be available.
-Educate patients about risk of hypersensitivity and to immediately report signs of hypersensitivity reactions.
-Explain the importance of routine blood cell counts.
-Have patients monitor their temperature frequently and immediately report fever.
-Explain the importance of taking corticosteroids as instructed.
-Inform patients of infection, dehydration, and renal failure risk; instruct patients to immediately report fever, significant vomiting or diarrhea, decreased urinary output, and hematuria.
More about cabazitaxel
Other brands: Jevtana